B. Riley Securities raised the price target for the Cassava Sciences Inc. (NASDAQ:SAVA) stock from “a Buy” to “a Neutral”. The rating was released on November 16, 2022, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $190. The stock was initiated by B. Riley Securities, who disclosed in a research note on April 27, 2021, to Buy and set the price objective to $78. In their research brief published February 16, 2021, H.C. Wainwright analysts reiterated the Cassava Sciences Inc. stock to Buy with a price target of $66.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Cassava Sciences Inc. (NASDAQ:SAVA) raised 4.59% to close Monday’s market session at $36.44, higher as compared to yesterday’s close. The stock price fluctuated between $34.50 and $38.53 throughout the trading session with the volume trading being 2160334 shares, which represented a significant variation when compared to the three months average volume of 1.25 million shares. The firm’s stock price fluctuated 7.18% within the last five trades and -3.42% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 58.92% in the last 6 months and 7.37% was added to its value over the previous 3 months. SAVA stock is trading at a margin of 15.22%, 5.21% and 23.57% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, SAVA deals in the Healthcare domain. The stock is trading -41.69 percent below its 52-week high and 163.29 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -1.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Cassava Sciences Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.44 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 7.35, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 2.70 percent of Cassava Sciences Inc. shares are owned by insiders, and 25.50 percent are held by financial institutions. Kupiec James William, the Chief Clinical Dev. Officer at Cassava Sciences Inc. (SAVA) has bought 2,500 shares of firm on Aug 23 at a price of $24.44 against the total amount of $61100.0. In another inside trade, Barry Richard, Director of Cassava Sciences Inc. (NASDAQ:SAVA) bought 36,159 shares of the firm on Aug 23 for a total worth of $0.86 million at a price of $23.79. An inside trade which took place on Aug 12, Chief Financial Officer of Cassava Sciences Inc. Schoen Eric bought 2,500 shares of firm against total price of $49875.0 at the cost of $19.95 per share.